×

Molecular Diagnostics - Global Strategic Business Report

Research and Markets logo

Dublin, Oct. 16, 2013 (GLOBE NEWSWIRE) -- Research and Markets (http://www.researchandmarkets.com/research/6898qb/molecular) has announced the addition of the "Molecular Diagnostics - Global Strategic Business Report" report to their offering.

This report analyzes the worldwide markets for Molecular Diagnostics in US$ million by the following Product Segments: Infectious Disease Testing, Pharmacogenomics, and Cancer Screening. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2010 through 2018. A six-year historic analysis is also provided for these markets.

The report profiles 103 companies including many key and niche players such as Abbott Laboratories, Abbott Molecular, Life Technologies Corporation, Celera, Biomérieux, CytoCore Inc., ELITech Group, GE Healthcare, Genzyme Corporation, Hologic, Inc., Laboratory Corporation of America® Holdings, MiraiBio, Inc., Novartis Diagnostics, QIAGEN N. V, Quest Diagnostics, Inc., Roche Diagnostics, Siemens Healthcare Diagnostics, and Tecan Group Ltd. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based upon search engine sources in the public domain.


Key Topics Covered:

I. Introduction, Methodology & Product Definitions

  • Study Reliability and Reporting Limitations I-1
  • Disclaimers I-2
  • Data Interpretation & Reporting Level I-2
  • Quantitative Techniques & Analytics I-3
  • Product Definitions and Scope of Study I-3
  • Infectious Diseases Testing I-3
  • Pharmacogenomics I-4
  • Cancer Screening I-4

II. Executive Summary

1. INDUSTRY OVERVIEW II-1

  • Global Market Outlook II-1
  • Molecular Diagnostics - A Quick Primer II-1
  • Molecular Diagnostics - The Fastest Growing Medical Diagnostic Technology II-1
  • Key Challenges to Growth II-2
  • Current and Future analysis II-2
  • US and Europe - Leaders in Molecular Diagnostics Adoption II-3
  • Developing Nations Offer Immense Potential II-3
  • Going Strong II-3
  • New Applications Hold Promising Potential II-4
  • Infectious Disease Testing Drives the Diagnostics Market II-4
  • The Future in Store II-5

2. A REVIEW OF MEDICAL DIAGNOSTICS MARKET II-6

  • Clinical Diagnostics Industry - Trends and Tendencies II-6
  • Diagnostic Tests - Classification II-7
  • Nucleic Acid Diagnostics Market - An Overview II-8
  • Molecular Diagnostics - Growth Drivers II-9
  • Molecular Diagnostics - A Replacement and Enabling Technology II-10
  • Molecular Diagnostics for Lymphoid Malignancies II-10

3. COMPETITIVE DYNAMICS IN THE MOLECULAR DIAGNOSTICS MARKET II-11

  • Competitive Landscape II-11
  • Key Players and Their Technologies II-11
  • The Top Tier II-11
  • Mid-Sized and Small Companies II-12
  • New Entrants Eye Unmet Needs II-12

4. MARKET TRENDS & ISSUES II-13

  • Market Consolidations on the Way to Integrate in Vivo and in Vitro Diagnostics II-13
  • Global Molecular Diagnostics on a High Growth Curve II-13
  • Automation Driving Global Market II-13
  • Molecular Diagnostics: Marking the Convergence of Numerous Technologies II-13
  • MDx Market for Infectious Diseases Zooming Ahead II-13
  • Aging Population, Disease Incidence - Fundamental Drivers of Growth II-14
  • Pharmaceutical Firms Carving Their Niche in Molecular Diagnostic Market II-14
  • Towards Tailoring the Right Treatment for the Right Disease II-14
  • Limited Reimbursements by Third Party Payers - A Stumbling Block II-15
  • Disease-Specific Molecular Diagnostics to Deliver Improved Clinical Outcomes II-15
  • Molecular Diagnostics and Intellectual Property II-15
  • Business Opportunities in the Offing II-16
  • Medical Training and Practice Challenges II-16
  • Hurdles All the Way for Companies Eyeing Molecular Diagnostics II-16
  • Product Marketing - Key to Commercial Success II-17
  • Integration of Molecular Diagnostics into Therapeutics II-17
  • Molecular Diagnostics - Moving from Centralization to Decentralization II-18
  • Migrating to Decentralized Format II-18
  • Going Ahead with Decentralization II-18

5. PRODUCT & TECHNOLOGY OVERVIEW II-20

  • Molecular Diagnostics - Definition & Scope II-20
  • Molecular Diagnostics - Impact on Healthcare II-20
  • Utility of Molecular Diagnostic Tests II-21
  • Background of Molecular Diagnostics II-21
  • Major Molecular Diagnostics Products II-21
  • Major Test Launches in Molecular Diagnostics in the Recent Past II-22
  • Unabated Developments in Molecular Diagnostics Technology II-22
  • Signal Amplification Technologies II-22
  • PCR - New Developments II-22
  • Major Applications of Real-Time PCR II-23
  • Quantitative Real-Time PCR for Molecular Diagnostics II-23
  • Signal Detection and Quantification II-23
  • Quantitative Real-Time RT-PCR Analysis II-24
  • Applications of Quantitative Real-Time PCR Analysis II-24
  • Viral Detection and Viral-Load Monitoring II-24
  • Sensitive Detection of Infectious Disease Agents II-24
  • Predisposition Testing II-24
  • Non-PCR Methods II-24
  • Other Signal Amplification Technologies II-24
  • DNA Probe Based Products II-24
  • Direct Detection of Specific Nucleic Acid Sequences II-25
  • Nucleic Acid Amplification and Detection II-25
  • DNA Sequencing and Gene Detection II-26
  • Arrays of Immobilized Probes (DNA Chips) in Gene Detection II-26
  • RNA Diagnostics II-26
  • Complementary Molecular Diagnostic Technologies II-27
  • Fluorescent In-Situ Hybridization (FISH) II-27
  • DNA Biochips / Microarrays II-27
  • Biosensors II-28
  • Proteomic Technologies for Molecular Diagnostics II-29
  • Nanotechnology for Molecular Diagnostics II-29
  • Technologies on the Anvil II-29
  • Haplotype Analysis - A Distant Possibility II-29
  • Chronic Multi-Gene Defects Now Diagnosable II-30

6. AN INSIGHT INTO APPLICATIONS OF MOLECULAR DIAGNOSTICS II-31

  • Infectious Diseases Testing II-31
  • Activity in the Field II-31
  • Identifying Multidrug Resistance II-32
  • Infectious Disease Treatment Monitoring II-32
  • Other Infectious Diseases Applications II-32
  • Genetic Disease Testing Applications II-32
  • Pharmacogenomics - Prognosis Based on Genomics II-33
  • Cancer Screening & Diagnosis II-33
  • Molecular Tests Lead the Way for Cancer IVD Market Growth II-34
  • Other Testing Applications II-35

7. RECENT INDUSTRY ACTIVITY II-36

  • Trovagene Acquires MultiGENs Clinical Laboratory Assets II-36
  • Qiagen Acquires Intelligent Bio-Systems II-36
  • Siemens Inks Agreements with Tocagen and ViiV Healthcare to Develop Companion Tests II-36
  • HTG Molecular Diagnostics Collaborates with Sanofi US II-36
  • DaAn Gene and Life Technologies Form Joint Venture II-37
  • Exosome Diagnostics and Life Technologies Ink Agreement II-37
  • GE Healthcare Acquires SeqWright II-38
  • Phthisis Diagnostics Expands its Distribution Network II-38
  • Luminex to Acquire GenturaDx II-39
  • Phthisis Diagnostics Inks Distribution Agreement with Genetix Biotech Asia II-39
  • Life Technologies Acquires Navigenics II-40
  • Abbott to Join Forces with Merck II-40
  • Signal Genetics to Acquire ChipDX LLC II-41
  • Quest Diagnostics Acquires S.E.D. Medical Laboratories II-41
  • Hologic Acquires Gen-Probe II-41
  • Accelerate Brain Cancer Cure Joins Hands with Exosome Diagnostics II-42
  • QIAGEN Collaborates with Cardinal Health II-42
  • LabCorp Acquires MEDTOX II-42
  • Genzyme Inks Agreement with Veracyte to Market Afirma Thyroid FNA Analysis Solution II-43
  • Celera Enters into Distribution Agreement with Abbott II-43
  • Sanofi-Aventis Acquires Genzyme II-43
  • Genzyme Divests Diagnostic Products Business to Sekisui Chemical II-43
  • Fortis Healthcares Offshore Subsidiary Acquires Controlling Stake in RadLink II-44
  • Agilent Technologies Inks Partnership Agreement with Integrated Diagnostics II-44
  • Genzyme to Divest Pharmaceutical Intermediates Business to ICIGs Affiliate II-44
  • Hologic Acquires Interlace Medical II-45
  • Applied BioCode Inks License and Supply Agreement with Hologic II-45
  • WuXi AppTec Partners with Qiagen II-45
  • OCM Acquisition Takes over Orchid Cellmark II-46
  • Modern Mobility Aids to Take Over LumiGene Technologies II-46
  • AmerisourceBergen Takes over Premier Source II-46
  • QIAGEN Acquires Cellestis II-47
  • QIAGEN Signs Agreement to Acquire Majority Interest in Ipsogen II-47
  • Novartis to Acquire Genoptix II-47
  • Vermillion Concludes Purchase of Correlogic's Ovarian Cancer Diagnostics Business II-47
  • VitaPath Genetics and Alere Enter into Strategic Partnership for Molecular Diagnostics II-48
  • Mingyuan Medicare to Purchase 70% Stake in Yuangi Bio II-48
  • Quest Diagnostics Acquires Athena Diagnostics II-48
  • Luminex Takes Over Eragen Biosciences II-49
  • Life Technologies Enters into Distribution Commercial Agreement for Quidel Assays II-49
  • BD and Diagenode Announce Agreement II-49
  • Gamma-Dynacare Buys Warnex Medical Laboratories II-50
  • OraSure Technologies to Takeover DNA Genotek II-50
  • Hologic Takes Over TCT International II-51
  • Affymetrix to Purchase eBioscience II-51
  • Sequenom Enters into Licensing Partnership with LifeCodexx II-51
  • LABSCO Inks Agreement with Cepheid II-52
  • Abbott to Expand GSK Agreement for Cancer Companion Diagnostic Test II-52
  • IntegenX Signs Distribution Agreement with Promega for RapidHIT Human Identification System II-52
  • BD Diagnostics Partners with Biodiversity for BD MAX Molecular Diagnostic Assays II-53
  • bioMérieux Acquires ARGENE II-53
  • Caliper Partners with Seegene to Expand Diagnostic Tests II-54
  • Enzo Clinical Labs Enters into Agreement with IncellDx II-54
  • Akonni and Seegene Ink Licensing Agreement II-55
  • Tecan Signs OEM Agreement with Major Diagnostics Company II-55
  • Tecan Inks License and Collaboration Agreement with Enigma II-55
  • Myriad Genetics Secures Option to Buy Crescendo Bioscience II-55
  • PerkinElmer Takes Over chemagen Biopolymer- Technologie AG II-56
  • Mayo Clinic Enters into Agreement with Rheonix II-56
  • Qiagen and Epigenomics Ink Option Agreement II-57

8. INDUSTRY ACTIVITY IN RECENT PAST - A PERSPECTIVE BUILDER II-58

  • ExonHit Therapeutics to Acquire RedPath Integrated Pathology II-58
  • Life Technologies Acquires AcroMetrix of Benicia II-58
  • Bar Harbor BioTechnology Establishes New Division II-58
  • SIRS-Lab Partners with Analytik Jena II-58
  • QIAGEN Enters into a Partnership with Genome Diagnostics II-59
  • IncellDx Enters into Supply Contract with Accuri II-59
  • BioMerieux Partners with Knome II-59
  • Caliper Enters into an Agreement with Access Genetics II-60
  • Debiopharm Group Forms Partnership with Biocartis II-60
  • AdnaGen AG Enters into a Contract with TATAA Molecular Diagnostics II-60
  • Roche Diagnostics Enters into Partnership with CapitalBio II-61
  • Epigenomics Signs Distribution Agreement with Epi proColon II-61
  • Genomic Health Selects IDBS to Provide Tools for Clinical Research II-61
  • TriLink BioTechnologies Signs Agreement with Biofortuna II-61
  • Pathwork Diagnostics Enters into Partnership with Novartis II-62
  • Affymetrix Signs Agreement with Signature Diagnostics II-62
  • Knome and bioMerieux Ink Exclusive Strategic Agreement II-62
  • GenMark Receives License to Innogenetics HCV Genotyping Patent II-63
  • GE Healthcare Takes Over Clarient II-63
  • Cypress to Sell Diagnostics Unit to Exagen II-63
  • EB Analytics Acquires EnviroLogix II-64
  • IRIS Takes over AlliedPath II-64
  • bioMerieux Takes Over Selected Assets of AnagnosTec II-64
  • Hologic Takes Over Sentinelle Medical II-64
  • Gen-Probe Takes Over GTI Diagnostics II-65
  • LabCorp Takes Over Genzyme Genetics II-65
  • bioMérieux Inks Agreement with Biocartis II-66
  • Genzyme Sells Genzyme Genetics to LabCorp II-66
  • Life Technologies Obtains IVD Marking for 7500 Fast Dx PCR Instrument II-66
  • Xenomics Changes Name to TrovaGene II-67
  • Abbott and GSK Team Up in the Area of Molecular Diagnosis II-67
  • Asuragen Enters Into Collaborations for Pancreatic Cancer Tests II-67
  • Transgenomic Licenses Intellectual Property from Integragen II-67
  • Health Discovery Inks Agreement with Pancreas, Biliary and Liver Surgery Center of New York II-68
  • Qiagen Enters into Agreement with Celera II-68
  • The Tecan Group Inks Agreement with Enigma II-68
  • Northeast Pharmaceuticals to Establish Biopharma JV with Shenyang II-69
  • Wescor Divests Microarray Technology Related Assets to Gamida For Life Group II-69
  • Predictive Biosciences Takes Over OncoDiagnostic Laboratory II-69
  • Applied Biosystems Obtains Approval for AmpFlSTR® MiniFiler™ PCR Amplification Kit II-70
  • Life Technologies Acquires AcroMetrix II-70
  • Ipsogen SA and The Institut Curie Enters into Scientific Collaboration Agreement II-70
  • bioTheranostics and Ferrer inCode Enters into Commercial Agreement II-70
  • Quidel Corp Signs Definitive Agreement to Purchase Diagnostic Hybrids II-71
  • Abbott Obtains CE Marking for New Diagnostic Test II-71
  • Transgenomic Enters into Licensing Agreement with Gene Solutions II-71
  • QIAGEN Acquires SABiosciences II-72
  • Corgenix Medical and BG Medicine Inks Supply Agreement II-72
  • Roche receives FDA Approval for Additional Usage of cobas® TaqScreen MPX Test II-72
  • Gen-Probe Obtains FDA Approval for Marketing of ProParaflu+TM Assay II-73
  • bioMerieux Enters into Agreement with GSK II-73
  • Tecan Group and Hologic Sign Agreement II-73
  • QIAGEN Takes Over DxS II-74
  • Tyrian Ends Partnership with Becton, Dickinson and Co II-74
  • Becton, Dickinson and Co to Purchase HandyLab II-74
  • Quidel and BioHelix Enter into Agreement II-75
  • Gen-Probe to Take Over Prodesse II-75
  • Summit Partners Acquires Stake in ApoCell II-75
  • Merck to form Alliance with QIAGEN II-75
  • Gen-Probe to Spin Off Industrial Testing Assets II-76
  • ImClone Systems and Bristol-Myers Squibb Enter into Collaboration with DxS II-76
  • Danaher to Acquire A Joint Venture Company II-76
  • Abbott Enters into Alliance with Pfizer for Molecular Diagnostic Test II-77
  • Rosetta and Warnex Ink Distribution Agreement II-77
  • ViraCor Laboratories Merges with IBT Laboratories II-77
  • ELITech Takes Over Assets of Nanogen II-77
  • LabCorp Signs Definitive Agreement with Monogram Biosciences II-78
  • Axial Biotech and University of Utah Enter into Collaboration II-78
  • Celera and Bayer Schering Pharma Sign Licensing Agreement II-78
  • AVESTHAGEN Enters into Collaboration with VTT Technical Research Centre II-79
  • 3M Terminates Collaboration Agreement with Gen-Probe II-79
  • BioGenex and Abbott Expand Joint Development and Distribution Agreement II-79
  • Pfizer Extends Collaboration Agreement with Monogram Biosciences II-80
  • BD Diagnostics Inks Agreement with HandyLab II-80
  • TriLink BioTechnologies and Osmetech Molecular Diagnostics Ink Agreement II-80
  • PerkinElmer Buys Analytica of Branford II-81
  • Ipsogen Signs Agreement with Arup Laboratories II-81
  • Prometheus Laboratories and Rosetta Genomics Ink Agreement II-81
  • AMDL and Precision Diagnostic Laboratory Signs Agreement II-81
  • Osmetech Signs Agreement with Fisher HealthCare II-82
  • Interleukin Genetics Inks Licensing Agreement with LABEC Pharma II-82
  • deCODE Genetics Inks Licensing Agreements with Celera II-82
  • Nuvera Biosciences Signs Licensing Agreement with Veridex II-83
  • GE Healthcare Inks Research Agreement with Brigham and Womens Hospital II-83
  • Gen-Probe Purchases Tepnel Life Sciences II-83
  • AdnaGen AG Receives US Patent II-83
  • Agilent Technologies Selects Asuragen as Certified Service Provider II-83
  • Genstruct Enters into Partnership with Gene Logic II-84
  • Lab21 Takes Over Biotec Laboratories II-84
  • ProGenTech and Innovative Biosensors Jointly Sign Extension Agreement II-84
  • Nanogen Signs and Scandinavian Gene Synthesis Inks Agreement II-85
  • Health Discovery Corporation Inks Licensing Agreement with Abbott II-85
  • BD Diagnostics Receives CE Marking for Amplified DNA Assays II-85
  • Transgenomic Signs Licensing Agreement Power3 Medical Products II-86
  • Rubicon Genomics and Abbott Enter into Licensing Agreement II-86
  • Novartis Extends Collaboration with Gen-Probe II-86
  • Eurogentec Receives ISO-Certification for IVD Oligonucleotides II-87
  • Dako and OSI Pharmaceuticals Enter into Collaboration II-87
  • Combimatrix Molecular Diagnostics and Lenetix Enter into Partnership II-87
  • Sequenom to Acquire AttoSense™ Tests of SensiGen II-87
  • Epigenomics AG and Sysmex Ink Research and Development Collaboration Deal II-88
  • Gene Express and Biogenuix Medsystems Signs Distribution Agreement II-88
  • Gene Express and Funakoshi Enter into Distribution Agreement II-89
  • BD and Company Obtains FDA Approval for Marketing GeneOhm™ Cdiff Test II-89
  • XDx and Bristol-Myers Squibb Company Signs Collaborative Agreement II-89
  • Rosetta Genomics and Teva Pharmaceutical Industries Signs Distribution Agreement II-90

9. PRODUCT DEVELOPMENTS/ INTRODUCTIONS II-91

  • Quest Diagnostics Introduces Cervical Cancer TERC Test II-91
  • BD Diagnostics Introduces Range of Open System Extraction and Master Mix Kits II-91
  • Pro-Lab Diagnostics Launches Portrait Analyser II-92
  • Quest Diagnostics Introduces Molecular Tests for Thyroid Cancer II-92
  • Seegene to Launch Quantitative TOCE Highly Multiplexed Quantitative Real-Time Molecular Technology II-92
  • ELITech Molecular Diagnostics Unveils 2nd Generation MRSA/SA ELITe MGB® Kit II-93
  • MDxHealth Introduces ConfirmMDx™ for Prostate Cancer Test II-93
  • Ipsos Healthcare Unveils Molecular Diagnostic Monitor Line II-94
  • Seegene Launches Anyplex™ MDR-TB Test II-94
  • Berg Diagnostics Introduces Molecular Diagnostics Offerings II-94
  • Life Technologies Unveils VetMAX™-Gold SIV Detection Kit II-95
  • Life Technologies Obtains Chinese Approval for Applied
  • Biosystems 3500 Dx / 3500xL Dx Genetic Analyzer II-95
  • LabCorp Launches HCV GenoSure NS3/4A II-96
  • Quest Diagnostics Launches AccuType IL28B Test II-96
  • Quest Diagnostics Unveils Simplexa™ Direct Test II-96
  • Quest Diagnostics Unveils Simplexa™ Dengue Test II-96

10. PRODUCT LAUNCHES IN RECENT PAST - A PERSPECTIVE BUILDER II-98

  • Quest Diagnostics Unveils Molecular Blood Test II-98
  • LabCorp Unveils IL-28B Test II-98
  • Gen-Probe Unveils ELUCIGENE™ KRAS.BRAF Kit II-98
  • QIAGEN Unveils QIAsymphony RGQ System II-99
  • Gen-Probe Unveils PANTHER™ System II-99
  • Life Technologies Unveils ViralSEQ™ Vesivirus Detection Kit II-99
  • Applied Biosystems New Forensic DNA Kits II-100
  • Quest Diagnostics Launches ColoVantage™ Test II-100
  • QIAGEN Introduces CE-labeled KRAS Kit II-100
  • Roche Introduces Cobas 4800 II-101
  • bioMérieux Launches Upgraded Version of NucliSENS EasyQ® Influenza A/B Test II-101
  • bioMérieux Introduces NucliSENS EasyQ® MRSA II-101
  • Roche Launches AMPLILINK 3.3 Series Software and cobas p 630 Instrument II-102
  • Applied Biosystems Unveils 3500 Series and 3500 DX Series Genetic Analyzer II-102
  • Prometheus Laboratories Introduces New Range of Cancer Diagnostic Products II-103
  • Sequenom Introduces SensiGene Cystic Fibrosis Carrier Screening Test II-103
  • Triplex and MedMira to Unveil New Rapid Tests II-103
  • Applied Biosystems to Introduce New Range of TaqMan® PCR Assays II-104
  • Quest Diagnostics Unveils HIV-1 Coreceptor Tropism Test II-104
  • Luminex introduced New Range of Cystic Fibrosis Tests II-104
  • bioMérieux Introduces VIDAS® EBV Test II-105
  • Luminex Unveils Two Novel Cystic Fibrosis Tests II-105
  • MEDomics Launches MitoDx™ for Diagnosing Mitochondrial Diseases II-105
  • Exagen Diagnostics Unveils eXaIBStest and eXaIBD Blood Tests II-106
  • bioMérieux Introduces NucliSENS EasyQ® HIV-1 v2.0 Test II-106
  • PreAnalytiX Introduces PAXgene® Blood miRNA Kit II-106
  • ViraCor Laboratories Introduces New JCV Test II-106
  • ViraCor Laboratories Rolls Out JC Virus Detection Test II-107
  • Focus Diagnostics Laboratory Introduces PCR Test II-107
  • Siemens Launches CLINITEK AUWi Urine Analyzing System II-107
  • Ocimum Biosolutions to Introduce New H1N1 Virus Detection Test II-108
  • Myriad Genetics Introduces OnDose for Cancer Diagnosis II-108
  • Applied Biosystems Introduces TaqMan® Array Gene Signature Plates II-108
  • GeneNews to Develop Blood-Based Diagnostic Tests II-109
  • Seegene Rolls Out Seeplex® Diarrhea ACE Detection Test II-109
  • Seegene Unveils Seeplex® Meningitis ACE Detection test II-109
  • Cepheid Introduces Xpert MRSA/SA Nasal Diagnostic Test II-110
  • Roche to Launch LightCycler Test II-110
  • Xenomics Unveils New Technology for Analyzing in Vivo Cell Death II-110
  • bioMerieux Unveils NucliSENS EasyQ® HPV Molecular Analytical Test II-111
  • Xenomics to Introduce Innovative Gender Prediction Test II-111
  • Evogen Unveils New EvoCycler™ HD12 Molecular Diagnostics System II-111
  • Siemens Healthcare Launches Innovance Antithrombin Test II-112
  • Rosetta Genomics Launches miRview™ meso Diagnostic Test II-112
  • ViraCor Laboratories Introduces Cytomegalovirus Antiviral Resistance Test II-112
  • Abbott Launches Diagnostic Test for HPV Detection II-113
  • Pathwork Diagnostics Introduces Tissue of Origin Test II-113
  • Evogen to Offer Diagnostic Tests II-114

11. FOCUS ON SELECT GLOBAL PLAYERS II-115

  • Abbott Laboratories (US) II-115
  • Abbott Molecular (US) II-115
  • Life Technologies Corporation (US) II-115
  • Celera (US) II-116
  • bioMérieux (France) II-116
  • CytoCore Inc. (US) II-117
  • ELITech Group (France) II-117
  • GE Healthcare (US) II-117
  • Genzyme Corp. (US) II-118
  • Hologic, Inc. (US) II-118
  • Laboratory Corporation of America® Holdings (US) II-119
  • MiraiBio, Inc. (US) II-119
  • Novartis Diagnostics (US) II-120
  • QIAGEN N.V (The Netherlands) II-120
  • Quest Diagnostics, Inc. (US) II-121
  • Roche Diagnostics (Switzerland) II-121
  • Siemens Healthcare Diagnostics Inc. (US) II-121
  • Tecan Group Ltd. (Switzerland) II-122
  • 12. GLOBAL MARKET PERSPECTIVE II-123



III. Market

1. THE UNITED STATES

2. CANADA

3. JAPAN

4. EUROPE

4a. FRANCE

4b. GERMANY

4c. ITALY

4d. THE UNITED KINGDOM

4e. REST OF EUROPE

5. ASIA-PACIFIC

6. REST OF WORLD

IV. Competitive Landscape

Companies Mentioned - FOR A FULL LIST, PLEASE CLICK HERE

  • Abbott Laboratories (USA)
  • BD Biosciences (USA)
  • bioTheranostics, Inc. (USA)
  • Cepheid, Inc. (USA)
  • DaAn Gene Co., Ltd. (China)
  • Danaher Corporation (USA)
  • DermTech International (USA)
  • Diagenode SA (Belgium)
  • GE Healthcare (UK)
  • GeneNews Ltd. (Canada)
  • Genomic Health, Inc. (USA)
  • Genzyme Corporation (USA)
  • Health Discovery Corporation (USA)
  • Illumina, Inc. (USA)
  • Immucor, Inc. (USA)
  • Incelldx, Inc. (USA)
  • Ipsogen SA (France)
  • Ipsos Healthcare (France)
  • Orchid Cellmark, Inc. (USA)
  • Life Technologies Corporation (USA)
  • Novartis Diagnostics (USA)
  • Orion Genomics (USA)
  • Qiagen NV (The Netherlands)
  • Quattromed Ltd. (Estonia)
  • Quest Diagnostics, Inc. (USA)
  • Roche Molecular Diagnostics (USA)
  • Trovagene, Inc. (USA)
  • Tyrian Diagnostics Ltd. (Australia)
  • Vascular Biosciences (USA)
  • Vermillion, Inc. (USA)


For more information visit http://www.researchandmarkets.com/research/6898qb/molecular

Research and Markets
Laura Wood, Senior Manager.
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Diagnostics

Source:Research and Markets